DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment

This study is based on an expanded access program in which 511 patients suffering from active refractory rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab (3 mg/kg+methotrexate (MTX)) at weeks 0, 2, 6 and every 8 weeks thereafter. At week 22, 474 patients were still in...

Descripción completa

Detalles Bibliográficos
Autores principales: Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van den Bosch, Filip, Veys, Eric M, Mielants, Herman, De Clerck, Luc, Peretz, Anne, Malaise, Michel, Verbruggen, Leon, Vastesaeger, Nathan, Geldhof, Anja, Boullart, Luc, De Keyser, Filip
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1257436/
https://www.ncbi.nlm.nih.gov/pubmed/16207323
http://dx.doi.org/10.1186/ar1787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1257436/
https://www.ncbi.nlm.nih.gov/pubmed/16207323
http://dx.doi.org/10.1186/ar1787

Ejemplares similares